Andrew Mackinnon, executive GM, Medable, explains how the company ensures high patient participation and data accuracy in ...
Data in and of itself can be interesting, but the true value of data lies in how you use it and the insights that come from ...
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
Intrathecal onasemnogene abeparvovec (OAV101 IT), an investigational, one-time gene replacement therapy, demonstrated a ...
COVID-19 not only advanced scientific boundaries, but also transformed research methodologies and accelerated adaptive ...
Recent research is showing medical treatment for pregnant women often relies on clinical data from non-pregnant female ...
Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...
In this video interview, Cameron Breze, product manager, Inovalon, discusses current challenges with patient recruitment and ...
New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...
In this video interview, Cameron Breze, product manager, Inovalon, highlights current trends with decentralization and how a dual approach can ensure flexibility across different therapeutic areas.
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...
The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback